Quick overview
- UnitedHealth Group (UNH) is trading at approximately $421.50, up 3.5% after a rebound from an October low of $362.74.
- The company reported Q3 results with an adjusted EPS of $4.69, exceeding expectations, and raised its full-year guidance for the third time this year.
- Despite a decline in revenue, operating margins improved significantly, indicating a focus on disciplined execution.
- Analysts have set price targets for UNH stock ranging from $427 to $504, with key resistance at the 61.8% Fibonacci level of $421.87.
Quick Answer: As of Tuesday, October 20, UnitedHealth Group (UNH) was trading at approximately $421.50, up around 3.5% on the day and extending a rebound from the $362.74 October low. The rebound is a continuation of a move stemming from the company’s Q3 results, which it said reflect “the discipline and execution” of its teams. The company also raised its full-year guidance for the third time this year, taking the 2026 adjusted EPS floor to $20.50. On the daily chart, the stock has broken a descending trendline from the July highs and is currently pressing the 61.8% Fibonacci level at $421.87.
My view: UNH is bullish as long as it trades above $399.37. A break above $421.87 would likely lead to a target of $440.19 and $458.51.
The Rally Extends a Week After a Beat-and-Raise Quarter
UNH was up around 3.51% on Tuesday, more than double the 1.54% move in the healthcare services and equipment sector. No news was reported to have caused the move. This puts Tuesday’s rally as an extension of the move the stock started on Wednesday, October 14, the day after the company reported Q3 results. For the quarter, UnitedHealth Group reported an adjusted EPS of $4.69, topping the $4.14 consensus, and the company cited “disciplined execution”. As a result, the company raised its full-year guidance to a minimum of $20.50, from its prior range of $19.50 to $20.00.
Margins Are Doing the Work, Not Revenue
Revenue during the quarter fell to $112.7 billion from $113.2 billion in the same quarter last year. However, earnings from operations improved to $6.6 billion from $4.3 billion, the medical care ratio improved to 88.4% from 89.9% and UnitedHealthcare’s operating margin improved to 3.3% from 2.1%. The company has purposely shed members. At the end of the quarter, UnitedHealthcare had 48.3 million members, down from 50.1 million a year earlier, and the company lost 935,000 members in its Medicare Advantage plans since year-end 2025.
I would say the quality of the margin is the more interesting question. The current quarter had $610 million of favorable prior-period reserve development. Management also said commercial cost trends are running above its initial 11% assumption, and its 2027 pricing is based on the assumption those costs would continue.
Optum’s Turnaround Supports the Re-Rating
In the quarter, Optum Health lost 10% of its revenue to $22.9 billion, largely due to the loss of value-based care patients. But it was still able to improve its operating earnings to $735 million, compared to $41 million last year. Optum’s other units also improved. OptumInsight improved earnings to $1.3 billion from $920 million and Optum Rx improved earnings to $1.7 billion from $1.5 billion. Optum Rx now has more than 50 percent of its membership from external clients, further reducing its reliance on UnitedHealthcare members. Operating cash flow of $5.1 billion, or 1.2 times net income, funded share repurchases and the $9.28 annual dividend.
The 2027 Outlook Is the Next Real Test
According to CFO Wayne DeVeydt on the latest earnings call, analyst consensus for 2027 “may understate the opportunity ahead.” DeVeydt added that a starting point for 2027 might be the low end of the company’s 13% to 16% long-term growth target, which is 13%. With 13% growth on the current $20.50 floor, we would see EPS at $23.17 in 2027, per calculations by Stocktwits. Management has said they will provide a more robust 2027 outlook by year-end.
Risks for 2027 are mainly with the company’s Medicare Advantage (MA) business. About 69% of members in 2027 are in 4-Star or greater plans; a reduction from the current year. Plus, about 390,000 members are in MA plans that will not be offered in 2027. Also, two Medicare Advantage investigations by the DOJ remain open.
Analyst Targets Cluster Just Above the Price
UNH’s stock price, about $421.50, puts it at 20.6 times the 2026 EPS floor and 18.2 times the implied 2027 EPS. Post-earnings targets cluster around these numbers. Baird cut its target to $427, Barclays to $440, and Raymond James to $450, per Benzinga. More bullish targets include $504 from Piper Sandler and $500 from Bernstein, which cut from $512. The stock trades just under the lower targets, and with the latest Q3 beat, and an anticipated 2027 outlook by year-end, I think the upside is greater than the 2027 outlook.
UNH Technical Analysis: Trendline Break Meets the 61.8% Fibonacci Test
UnitedHealth is currently trading at $421.50, a 3.5% gain on the day, and is extending a sharp rebound after dropping to $362.74 in October, which was close to the 200 day EMA. The stock has not only cleared the 50 day EMA at $388.37, but also a descending trend line from the July peak, making the near term trend bullish. One thing worth noting is that price has reached the 61.8% Fibonacci retracement level at $421.87, which is often a make-or-break level and in this case could indicate where the recent recovery stops.
The 14 day relative strength index (RSI) has hit an overbought level at 72.10, the first time this has happened since May. Similar to the above reasoning, I view this as a caution flag. Above current resistance at $421.87, the next resistance levels are $440.19, which is the Barclays price target, and then the July high at $458.51.
The current level of support at $410.51 is also the 50% Fibonacci retracement level. Below that is support at $399.37, which is the 38.2% Fibonacci retracement level, and below that the key level at $388.37 to $385.23, which is where the 50 day EMA meets the 23.6% Fibonacci retracement, and below that is the 200 day EMA and the October low at $362.74. I am bullish as long as UnitedHealth remains above $399.37. A break below that level would put focus on $388.37 and $385.23 and a close below the 50 day EMA would also be bearish.
- Resistance: $421.87 | $440.19 | $458.51
- Support: $410.51 | $399.37 | $388.37 | $385.23 | $372.34 | $362.74
FAQs
Why is UnitedHealth stock up today?
UnitedHealth Group (UNH) extended its post-earnings rally on Tuesday after reporting Q3 results and raising its 2026 guidance for the third time. UNH stock gained about 3.5% on the day, more than double the gain of the healthcare services sector.
What is the next resistance for UNH stock?
The key level is the 61.8% Fibonacci retracement level at $421.87. A daily close above that level opens up $440.19 and the July high at $458.51.
When will UnitedHealth give its 2027 outlook?
Management has stated they would issue a fuller 2027 outlook by year-end. They have not specified a date, but results for Q4 are expected to be released in late January 2027.
Arslan Ali Butt
Lead Markets Analyst – Multi-Asset (FX, Commodities, Crypto)
Arslan Ali Butt serves as the Lead Commodities and Indices Analyst, bringing a wealth of expertise to the field. With an MBA in Behavioral Finance and active progress towards a Ph.D., Arslan possesses a deep understanding of market dynamics.
His professional journey includes a significant role as a senior analyst at a leading brokerage firm, complementing his extensive experience as a market analyst and day trader. Adept in educating others, Arslan has a commendable track record as an instructor and public speaker.
His incisive analyses, particularly within the realms of cryptocurrency and forex markets, are showcased across esteemed financial publications such as ForexCrunch, InsideBitcoins, and EconomyWatch, solidifying his reputation in the financial community.
